Antigen Information

General Information of This Antigen
Antigen ID
TAR0FPXYP
Antigen Name
Undisclosed
Gene Name
Undisclosed
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Monoclonal antibody 45-2D9-haematoporphyrin conjugate
Hematoporphyrin
Undisclosed
Undisclosed
 [1]
Anti-B-cell mAb SN7
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Monoclonal antibody SN7-ricin chain A conjugate
Deglycosylated ricin A-chain (dgA)
Undisclosed
Undisclosed
 [2]
Rabbit derived VL single-domain Anti-ody
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
ROS-responsive SN38 ADC
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-Cyc-PEG3-DAB
 [3]
 ADC Info 
VL-DAB31-SN38
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-Cyc-PEG3-DAB
 [3]
Undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
DB-1202
Undisclosed
Unclear
Undisclosed
 [4]
 ADC Info 
CPO-204
Undisclosed
Unclear
Undisclosed
 [5]
 ADC Info 
DXC-009
Undisclosed
Unclear
Undisclosed
 [6]
 ADC Info 
MG-1901
Undisclosed
Unclear
Undisclosed
 [7]
 ADC Info 
MG-2001
Undisclosed
Unclear
Undisclosed
 [7]
 ADC Info 
MG-2002A
Undisclosed
Unclear
Undisclosed
 [7]
 ADC Info 
PHN-010
DNA topoisomerase-I inhibitor
DNA topoisomerase 1 (TOP1)
Undisclosed
 [8]
 ADC Info 
SC-005
PDB
Human Deoxyribonucleic acid (hDNA)
Undisclosed
 ADC Info 
SC-007
Undisclosed
Unclear
Undisclosed
 [9]
 ADC Info 
3-NAntC
Undisclosed
Undisclosed
Undisclosed
 [10]
 ADC Info 
AbGn-108
Undisclosed
Undisclosed
Undisclosed
 [11]
 ADC Info 
AccuADC-001
Undisclosed
Undisclosed
Undisclosed
 [12]
 ADC Info 
ADC project 4 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
 [13]
 ADC Info 
ADC project 5 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
 [13]
 ADC Info 
ADC project 6 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
 [13]
 ADC Info 
ADC001 (Arbele)
Undisclosed
Undisclosed
Undisclosed
 [14]
 ADC Info 
AMB-015
Undisclosed
Undisclosed
Undisclosed
 [15]
 ADC Info 
AMB-101
Topoisomerase I inhibitor
DNA topoisomerase 1 (TOP1)
Undisclosed
 [16]
 ADC Info 
ANG-101
Undisclosed
Undisclosed
Undisclosed
 [17]
 ADC Info 
Antibody targeted amanitin conjugate
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
 [18]
 ADC Info 
Antibody-drug conjugate containing OXS-2175 (Oxis Biotech/MultiCell ImmunoTherapeutics)
Undisclosed
Undisclosed
Undisclosed
 [19]
 ADC Info 
Anticancer antibody-drug conjugate (Vaccinex/Catalent Pharma Solutions)
Undisclosed
Undisclosed
Undisclosed
 [20]
 ADC Info 
APH-0912
Docetaxel
Microtubule (MT)
Hydrophilic linker containing sugar molecules
 [21]
 ADC Info 
AR081
Undisclosed
Undisclosed
Undisclosed
 [22]
 ADC Info 
AVP20
Undisclosed
Undisclosed
Undisclosed
 [23]
 ADC Info 
BC5084
Undisclosed
Undisclosed
Undisclosed
 [24]
 ADC Info 
BIO103
Undisclosed
Undisclosed
Undisclosed
 [25]
 ADC Info 
BIO104
Undisclosed
Undisclosed
Undisclosed
 [25]
 ADC Info 
BIO-107
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
BIO-108
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
BIO-109
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
BIO-110
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
BIO-112
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
BIO-201
Undisclosed
Undisclosed
Undisclosed
 [26]
 ADC Info 
Bi-specific antibody drug conjugate
Undisclosed
Undisclosed
Undisclosed
 [27]
 ADC Info 
BL-B029A1
Undisclosed
Undisclosed
Undisclosed
 [28]
 ADC Info 
BL-M002A2
Undisclosed
Undisclosed
Undisclosed
 [29]
 ADC Info 
BL-M005
Undisclosed
Undisclosed
Undisclosed
 [30]
 ADC Info 
BL-M005A2
Dual-warhead
Undisclosed
Undisclosed
 [31]
 ADC Info 
BL-M22D1
Undisclosed
Undisclosed
Undisclosed
 [32]
 ADC Info 
BL-M25D1
Undisclosed
Undisclosed
Undisclosed
 [32]
 ADC Info 
BMT-125961
Undisclosed
Undisclosed
Undisclosed
 [33]
 ADC Info 
BP-A102
Undisclosed
Undisclosed
Undisclosed
 [34]
 ADC Info 
BP-A103
Undisclosed
Undisclosed
Undisclosed
 [34]
 ADC Info 
BR109
Undisclosed
Undisclosed
Undisclosed
 [35]
 ADC Info 
BRKB-28
Undisclosed
Undisclosed
Undisclosed
 [36]
 ADC Info 
BsAb-ADC (Medilink Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [37]
 ADC Info 
BSC-4101
Undisclosed
Undisclosed
Undisclosed
 [38]
 ADC Info 
BSC-4201
Undisclosed
Undisclosed
Undisclosed
 [39]
 ADC Info 
CAT-03-106
Undisclosed
Undisclosed
Undisclosed
 [40]
 ADC Info 
CBP-1609
Undisclosed
Undisclosed
Undisclosed
 [41]
 ADC Info 
CBX-13
Mertansine DM4
Microtubule (MT)
Undisclosed
 [42]
 ADC Info 
CBX-14
Multi-targetd DDR inhibitor
Epithelial discoidin domain-containing receptor 1 (DDR1)
Undisclosed
 [42]
 ADC Info 
CM-09
Undisclosed
Undisclosed
Undisclosed
 [43]
 ADC Info 
CS-5002
Undisclosed
Undisclosed
Undisclosed
 [44]
 ADC Info 
DN-028
Undisclosed
Undisclosed
Undisclosed
 [45]
 ADC Info 
DXC-010
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-011
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-012
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-013
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-014
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-015
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-016
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-017
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-018
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-019
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
DXC-020
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
EP-400
Undisclosed
Undisclosed
Undisclosed
 [46]
 ADC Info 
EX108
Undisclosed
Undisclosed
Undisclosed
 [47]
 ADC Info 
FG-M131
Undisclosed
Undisclosed
Undisclosed
 [48]
 ADC Info 
G-100 (Magenta Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [49]
 ADC Info 
GF-2014
Undisclosed
Undisclosed
Undisclosed
 [50]
 ADC Info 
GMA-205
Undisclosed
Undisclosed
Undisclosed
 [51]
 ADC Info 
GQ1011
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
GR1018
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
HDP-104
Undisclosed
Undisclosed
Undisclosed
 [53]
 ADC Info 
HY-0001
Undisclosed
Undisclosed
Undisclosed
 [54]
 ADC Info 
IKS-02
Undisclosed
Undisclosed
Undisclosed
 [55]
 ADC Info 
IKS-04
Undisclosed
Undisclosed
Undisclosed
 [55]
 ADC Info 
IMB-212
Undisclosed
Undisclosed
Undisclosed
 [56]
 ADC Info 
IMB-213I
Undisclosed
Undisclosed
Undisclosed
 [56]
 ADC Info 
JY-023
Undisclosed
Undisclosed
Undisclosed
 [57]
 ADC Info 
JY208
Undisclosed
Undisclosed
Undisclosed
 [58]
 ADC Info 
JY210
Undisclosed
Undisclosed
Undisclosed
 [58]
 ADC Info 
KGX201
Undisclosed
Undisclosed
Undisclosed
 [59]
 ADC Info 
LCB14-15nm
Undisclosed
Undisclosed
Undisclosed
 [60]
 ADC Info 
LCB-69
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-91
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LM-001
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-004
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-005
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-006
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-007
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-008
Undisclosed
Undisclosed
Undisclosed
 [62]
 ADC Info 
LM-317
Undisclosed
Undisclosed
Undisclosed
 [63]
 ADC Info 
MBK-101
Undisclosed
Undisclosed
Undisclosed
 [64]
 ADC Info 
MG2002B
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
MG2011C
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
MG2106E
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
Monoclonal Antibody-Drug Conjugate (Antengene)
Undisclosed
Undisclosed
Undisclosed
 [65]
 ADC Info 
Monoclonal Antibody-Drug Conjugate (Kind Pharmaceuticals)
Undisclosed
Undisclosed
Undisclosed
 [66]
 ADC Info 
MRX-23
Undisclosed
Undisclosed
Undisclosed
 [67]
 ADC Info 
NBE-001
Undisclosed
Undisclosed
Undisclosed
 [68]
 ADC Info 
NBE-003
Undisclosed
Undisclosed
Undisclosed
 [69]
 ADC Info 
NBT-528
Undisclosed
Undisclosed
Undisclosed
 [70]
 ADC Info 
NBT-568
Undisclosed
Undisclosed
Undisclosed
 [71]
 ADC Info 
NBT-578
Undisclosed
Undisclosed
Undisclosed
 [72]
 ADC Info 
Next generation antibody-drug conjugate (Oxford BioTherapeutics)
Undisclosed
Undisclosed
Undisclosed
 [73]
 ADC Info 
NTX-1107
Undisclosed
Undisclosed
Undisclosed
 [74]
 ADC Info 
NW-001
Undisclosed
Undisclosed
Undisclosed
 [75]
 ADC Info 
OBT029
Undisclosed
Undisclosed
Undisclosed
 [76]
 ADC Info 
OBT207
Undisclosed
Undisclosed
Undisclosed
 [76]
 ADC Info 
OBT542
Undisclosed
Undisclosed
Undisclosed
 [76]
 ADC Info 
OX-004
Undisclosed
Undisclosed
Undisclosed
 [77]
 ADC Info 
P-1000
Undisclosed
Undisclosed
Undisclosed
 [78]
 ADC Info 
P-BsAb-ADC
Undisclosed
Undisclosed
Undisclosed
 [79]
 ADC Info 
PCG-C002
Undisclosed
Undisclosed
Undisclosed
 [80]
 ADC Info 
PCG-C004
Undisclosed
Undisclosed
Undisclosed
 [80]
 ADC Info 
PCG-C006
Undisclosed
Undisclosed
Undisclosed
 [80]
 ADC Info 
PCG-N003
Undisclosed
Undisclosed
Undisclosed
 [80]
 ADC Info 
PHN-020
Undisclosed
Undisclosed
Undisclosed
 [8]
 ADC Info 
PLBA-001
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PSM-101
Undisclosed
Undisclosed
Undisclosed
 [82]
 ADC Info 
PTM-001-ADC
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
 [83]
 ADC Info 
RAD-501
Undisclosed
Undisclosed
Undisclosed
 [84]
 ADC Info 
SDV-1001
Undisclosed
Undisclosed
Undisclosed
 [85]
 ADC Info 
SeeloMab-GEX
Undisclosed
Undisclosed
Undisclosed
 [86]
 ADC Info 
SGN-25
Undisclosed
Undisclosed
Undisclosed
 [87]
 ADC Info 
SIB-004A
Undisclosed
Undisclosed
Undisclosed
 [88]
 ADC Info 
SIM-002A
Undisclosed
Undisclosed
Undisclosed
 [89]
 ADC Info 
SIM-005A
Undisclosed
Undisclosed
Undisclosed
 [90]
 ADC Info 
SMD-3117
Undisclosed
Undisclosed
Undisclosed
 [91]
 ADC Info 
SMP-190
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Unique hydrophilic Linker
 [92]
 ADC Info 
SO-N107
Undisclosed
Undisclosed
Undisclosed
 [93]
 ADC Info 
SOT106
Undisclosed
Undisclosed
Undisclosed
 [94]
 ADC Info 
Spliceostatin-antibody-drug conjugate
Spliceostatin A
Splicing factor 3B subunit 1 (SF3B1)
Undisclosed
 [95]
 ADC Info 
STING agonist ADC
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
 [96]
 ADC Info 
SY-0625
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-0833
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-1211
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-1558
Undisclosed
Undisclosed
Undisclosed
 [98]
 ADC Info 
TAE-020
Undisclosed
Undisclosed
Undisclosed
 [99]
 ADC Info 
TAK-ATACs
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
 [100]
 ADC Info 
TT-01
Undisclosed
Undisclosed
Undisclosed
 [101]
 ADC Info 
TUB-050
Undisclosed
Undisclosed
Undisclosed
 [102]
 ADC Info 
TUB-060
Undisclosed
Undisclosed
Undisclosed
 [102]
 ADC Info 
VIS-705
Undisclosed
Undisclosed
Undisclosed
 [103]
 ADC Info 
VLS-201
Undisclosed
Undisclosed
Undisclosed
 [104]
 ADC Info 
WTX-222
Undisclosed
Undisclosed
Undisclosed
 [105]
 ADC Info 
WTX-231
Undisclosed
Undisclosed
Undisclosed
 [105]
 ADC Info 
XMT-2068
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
 [106]
 ADC Info 
XMT-2175
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
 [106]
 ADC Info 
RC-168
Undisclosed
Undisclosed
Undisclosed
 [107]
 ADC Info 
RC-178
Undisclosed
Undisclosed
Undisclosed
 [107]
 ADC Info 
RC-188
Undisclosed
Undisclosed
Undisclosed
 [107]
 ADC Info 
XNW-28012
Undisclosed
Undisclosed
Undisclosed
 [108]
 ADC Info 
XYD-9668-198
Undisclosed
Undisclosed
Undisclosed
 [109]
 ADC Info 
131I-ImmuRAIT-HCG
Undisclosed
Undisclosed
Undisclosed
 [110]
 ADC Info 
NBT-588
Undisclosed
Undisclosed
Undisclosed
 [111]
 ADC Info 
NBT-588
Undisclosed
Undisclosed
Undisclosed
 [111]
 ADC Info 
ADC project 7 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
 [13]
 ADC Info 
ADC002 (Arbele)
Undisclosed
Undisclosed
Undisclosed
 [14]
 ADC Info 
ADC003 (Arbele)
Undisclosed
Undisclosed
Undisclosed
 [14]
 ADC Info 
ADC2154
Undisclosed
Undisclosed
Undisclosed
 [112]
 ADC Info 
ADC2231
Undisclosed
Undisclosed
Undisclosed
 [113]
 ADC Info 
ADC2313
Undisclosed
Undisclosed
Undisclosed
 [114]
 ADC Info 
ADC2317
Undisclosed
Undisclosed
Undisclosed
 [115]
 ADC Info 
ADC2335
Undisclosed
Undisclosed
Undisclosed
 [116]
 ADC Info 
Additional antibody drug conjugate (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [117]
 ADC Info 
ADRX-863
Undisclosed
Undisclosed
Undisclosed
 [118]
 ADC Info 
Advanced antibody drug conjugate (Belrose Pharma)
Undisclosed
Undisclosed
Undisclosed
 [119]
 ADC Info 
AK 30 NGF
Undisclosed
Undisclosed
Undisclosed
 [120]
 ADC Info 
Alpha-amanitin antibody-drug conjugate (Agensys)
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
 [121]
 ADC Info 
AMB-102
Undisclosed
Undisclosed
Undisclosed
 [122]
 ADC Info 
Antibody boron conjugate radiopharmaceuticals (TAE Life Sciences)
Undisclosed
Undisclosed
Undisclosed
 [123]
 ADC Info 
Antibody drug conjugate (Halozyme)
Undisclosed
Undisclosed
Undisclosed
 [124]
 ADC Info 
Antibody drug conjugate containing duocarmycin analogue
Undisclosed
Undisclosed
Undisclosed
 [125]
 ADC Info 
Antibody-drug conjugate (Oxford BioTherapeutics/Boehringer Ingelheim)
Undisclosed
Undisclosed
Undisclosed
 [126]
 ADC Info 
Antibody-drug conjugate (Sanofi/Seagen)
Undisclosed
Undisclosed
Undisclosed
 [127]
 ADC Info 
Antibody-drug conjugate (SynAffix)
Undisclosed
Undisclosed
Undisclosed
 [128]
 ADC Info 
Antibody-drug conjugate 3 (Synthon)
Undisclosed
Undisclosed
Undisclosed
 [129]
 ADC Info 
Antibody-drug conjugate 4 (Synthon)
Undisclosed
Undisclosed
Undisclosed
 [130]
 ADC Info 
Anti-cancer therapeutic (Amgen)
Undisclosed
Undisclosed
Undisclosed
 [131]
 ADC Info 
Antiviral Fc-conjugate (Cidara Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [132]
 ADC Info 
APB-CS
Undisclosed
Undisclosed
Undisclosed
 [133]
 ADC Info 
APEC-2
Undisclosed
Undisclosed
Undisclosed
 [134]
 ADC Info 
APEC-3
Undisclosed
Undisclosed
Undisclosed
 [135]
 ADC Info 
AT-00
Undisclosed
Undisclosed
Undisclosed
 [136]
 ADC Info 
AT-01
Undisclosed
Undisclosed
Undisclosed
 [137]
 ADC Info 
AT-03
Undisclosed
Undisclosed
Undisclosed
 [137]
 ADC Info 
AT-04
Undisclosed
Undisclosed
Undisclosed
 [137]
 ADC Info 
AU-011
IRDye 700DX
Undisclosed
Undisclosed
 [138]
 ADC Info 
BB-1706
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BB-1708
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BB-1710
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BB-1712
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BIO105
Undisclosed
Undisclosed
Undisclosed
 [140]
 ADC Info 
BIOO-1
Undisclosed
Undisclosed
Undisclosed
 [141]
 ADC Info 
BIOO-2
Undisclosed
Undisclosed
Undisclosed
 [142]
 ADC Info 
BIOO-3
Undisclosed
Undisclosed
Undisclosed
 [143]
 ADC Info 
BIOO-4
Undisclosed
Undisclosed
Undisclosed
 [144]
 ADC Info 
BR107
Undisclosed
Undisclosed
Undisclosed
 [145]
 ADC Info 
BR-2003
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BR-2102
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BR-2202
Undisclosed
Undisclosed
Undisclosed
 [139]
 ADC Info 
BRKB-44
Undisclosed
Undisclosed
Undisclosed
 [146]
 ADC Info 
BRY811
Undisclosed
Undisclosed
Undisclosed
 [147]
 ADC Info 
BSI-023
Undisclosed
Undisclosed
Undisclosed
 [148]
 ADC Info 
CO-1003
Undisclosed
Undisclosed
Undisclosed
 [149]
 ADC Info 
CO-1023
Undisclosed
Undisclosed
Undisclosed
 [149]
 ADC Info 
CRB-2107
Undisclosed
Undisclosed
Undisclosed
 [150]
 ADC Info 
CS5005
Undisclosed
Undisclosed
Undisclosed
 [151]
 ADC Info 
CS5006
Undisclosed
Undisclosed
Undisclosed
 [151]
 ADC Info 
CT-P26
Undisclosed
Undisclosed
Undisclosed
 [152]
 ADC Info 
DBAF-301
Undisclosed
Undisclosed
Undisclosed
 [153]
 ADC Info 
DN-027
Undisclosed
Undisclosed
Undisclosed
 [154]
 ADC Info 
DOM-1314
Undisclosed
Undisclosed
Undisclosed
 [155]
 ADC Info 
Dual-payload ADC (Mersana Therapeutics)
AF-HPA+DNA monoalkylator I-BiP
Microtubule (MT); Human Deoxyribonucleic acid (hDNA)
Undisclosed
 [156]
 ADC Info 
Eribulin ADC (Jiangsu hengrui)
Eribulin
Microtubule (MT)
Undisclosed
 [157]
 ADC Info 
EVOLVE-104 ADC
Undisclosed
Undisclosed
Undisclosed
 [158]
 ADC Info 
FG-B310
Undisclosed
Undisclosed
Undisclosed
 [48]
 ADC Info 
GBM-12401
Undisclosed
Undisclosed
Undisclosed
 [159]
 ADC Info 
GL-231
Undisclosed
Undisclosed
Undisclosed
 [160]
 ADC Info 
Glaucoma therapy
Undisclosed
Undisclosed
Undisclosed
 [161]
 ADC Info 
GMA-305
Undisclosed
Undisclosed
Undisclosed
 [162]
 ADC Info 
GQ-1009
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
GR-1014
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
GR-1015
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
GR-1016
Undisclosed
Undisclosed
Undisclosed
 [52]
 ADC Info 
IBI130
Undisclosed
Undisclosed
Undisclosed
 [163]
 ADC Info 
IMB-202
Undisclosed
Undisclosed
Undisclosed
 [164]
 ADC Info 
IN30718
Undisclosed
Undisclosed
Undisclosed
 [165]
 ADC Info 
IN30728
Undisclosed
Undisclosed
Undisclosed
 [166]
 ADC Info 
IOG-101
Undisclosed
Undisclosed
Undisclosed
 [167]
 ADC Info 
LCB-02A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-04A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-06A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-09A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-12A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-18A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-19A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-20A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-42A
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-85
Undisclosed
Undisclosed
Undisclosed
 [61]
 ADC Info 
LCB-88
Undisclosed
Undisclosed
Undisclosed
 [168]
 ADC Info 
LD016
Undisclosed
Undisclosed
Undisclosed
 [169]
 ADC Info 
LEAD ADC (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [170]
 ADC Info 
LP-A18
Undisclosed
Undisclosed
Undisclosed
 [171]
 ADC Info 
M-131
Undisclosed
Undisclosed
Undisclosed
 [172]
 ADC Info 
MABS-01
Undisclosed
Undisclosed
Undisclosed
 [173]
 ADC Info 
MABS-02
Undisclosed
Undisclosed
Undisclosed
 [173]
 ADC Info 
Masked ADC (Adagene/ADC Therapeutics)
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Undisclosed
 [174]
 ADC Info 
MBC-301
Undisclosed
Undisclosed
Undisclosed
 [175]
 ADC Info 
MG2018
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
Monoclonal Antibody-Drug conjugate (Celltrion Chemical Research Institute/Immunogen/Celltrion)
Undisclosed
Undisclosed
Undisclosed
 [176]
 ADC Info 
MRG-006
Undisclosed
Undisclosed
Undisclosed
 [177]
 ADC Info 
NBT-598
Undisclosed
Undisclosed
Undisclosed
 [178]
 ADC Info 
NW-12-005
Undisclosed
Undisclosed
Undisclosed
 [179]
 ADC Info 
NX-08
Undisclosed
Undisclosed
Undisclosed
 [180]
 ADC Info 
OTV:CH2
Undisclosed
Undisclosed
Undisclosed
 [181]
 ADC Info 
OTV:LF3
Undisclosed
Undisclosed
Undisclosed
 [181]
 ADC Info 
PBX-002
Undisclosed
Undisclosed
Undisclosed
 [182]
 ADC Info 
PLBA-002
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBA-003
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBA-004
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBA-005
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBC-001
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBC-002
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
PLBC-003
Undisclosed
Undisclosed
Undisclosed
 [81]
 ADC Info 
SAB-Y1
Undisclosed
Undisclosed
Undisclosed
 [183]
 ADC Info 
SAB-Y17
Undisclosed
Undisclosed
Undisclosed
 [183]
 ADC Info 
Second ADC (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [184]
 ADC Info 
SMD-5033
Undisclosed
Undisclosed
Undisclosed
 [185]
 ADC Info 
STING based antibody-drug conjugate (Exelixis)
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
 [186]
 ADC Info 
SY-0831
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-1274
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-1330
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
SY-1700
Undisclosed
Undisclosed
Undisclosed
 [97]
 ADC Info 
TGM-002
Undisclosed
Undisclosed
Undisclosed
 [187]
 ADC Info 
TGM-003
Undisclosed
Undisclosed
Undisclosed
 [188]
 ADC Info 
TGM-004
Undisclosed
Undisclosed
Undisclosed
 [189]
 ADC Info 
TGM-005
Undisclosed
Undisclosed
Undisclosed
 [190]
 ADC Info 
TST013
Undisclosed
Undisclosed
Undisclosed
 [191]
 ADC Info 
Vas-201
Undisclosed
Undisclosed
Undisclosed
 [192]
 ADC Info 
Vas-202
Undisclosed
Undisclosed
Undisclosed
 [193]
 ADC Info 
VLS-301
Undisclosed
Undisclosed
Undisclosed
 [194]
 ADC Info 
WTX-116
Undisclosed
Undisclosed
Undisclosed
 [105]
 ADC Info 
ZV03-ADC
Undisclosed
Undisclosed
Undisclosed
 [195]
 ADC Info 
Antibody drug conjugate (Asana BioSciences)
Undisclosed
Undisclosed
Undisclosed
 [196]
 ADC Info 
Antibody drug conjugate (Compugen)
Undisclosed
Undisclosed
Undisclosed
 [197]
 ADC Info 
Antibody drug conjugate (Five Prime cancer)
Undisclosed
Undisclosed
Undisclosed
 [198]
 ADC Info 
Antibody drug conjugate (Intrexon)
Undisclosed
Undisclosed
Undisclosed
 [199]
 ADC Info 
Antibody drug conjugate (Meditope Biosciences)
Undisclosed
Undisclosed
Undisclosed
 [200]
 ADC Info 
Antibody drug conjugate (Sanofi)
Undisclosed
Undisclosed
Undisclosed
 [201]
 ADC Info 
Antibody-drug conjugate (Bristol-Myers Squibb)
Undisclosed
Undisclosed
Undisclosed
 [202]
 ADC Info 
Antibody-drug conjugate (Daiichi Sankyo)
Undisclosed
Undisclosed
Undisclosed
 [203]
 ADC Info 
Antibody-drug conjugate (University of Toronto/Advanced Proteome Therapeutics)
Undisclosed
Undisclosed
Undisclosed
 [204]
 ADC Info 
Antibody-drug conjugate (University of Toronto/ImmunoBiochem)
Undisclosed
Undisclosed
Undisclosed
 [205]
 ADC Info 
Antibody-drug conjugate therapy (Neoantigenics)
Undisclosed
Undisclosed
Undisclosed
 [206]
 ADC Info 
BIOO-5
Undisclosed
Undisclosed
Undisclosed
 [207]
 ADC Info 
BIOO-6
Undisclosed
Undisclosed
Undisclosed
 [208]
 ADC Info 
BIOO-7
Undisclosed
Undisclosed
Undisclosed
 [209]
 ADC Info 
CRC-02 targeting antibody-drug conjugate
Undisclosed
Undisclosed
Undisclosed
 [210]
 ADC Info 
CYP-Ab
Undisclosed
Undisclosed
Undisclosed
 [211]
 ADC Info 
KSI-201
Undisclosed
Undisclosed
Undisclosed
 [212]
 ADC Info 
LCB14-2nm
Undisclosed
Undisclosed
Undisclosed
 [213]
 ADC Info 
LIN-003
Undisclosed
Undisclosed
Undisclosed
 [214]
 ADC Info 
Marine-derived cytotoxic payloads antibody-drug conjugation
Undisclosed
Undisclosed
Undisclosed
 [215]
 ADC Info 
Monovalent Azymatic Antibody Drug Conjugate (Zymeworks)
Undisclosed
Undisclosed
Undisclosed
 [216]
 ADC Info 
MRG-005
Undisclosed
Undisclosed
Undisclosed
 [217]
 ADC Info 
MRG-007
Undisclosed
Undisclosed
Undisclosed
 [218]
 ADC Info 
MRG-008
Undisclosed
Undisclosed
Undisclosed
 [219]
 ADC Info 
MRG-009
Undisclosed
Undisclosed
Undisclosed
 [220]
 ADC Info 
Multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene)
Undisclosed
Undisclosed
Undisclosed
 [221]
References
Ref 1 Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg Oncol. 1993;2(1):31-42. doi: 10.1016/0960-7404(93)90042-w.
Ref 2 Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. Cancer Res. 1997 Feb 15;57(4):678-85.
Ref 3 Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25914-25921. doi: 10.1002/anie.202109835. Epub 2021 Nov 5.
Ref 4 A Study of DB-1202 Monotherapy in Advanced Solid Tumors.
Ref 5 Antibody-drug conjugate CPO204 obtains clinical trial approval in the U.S.
Ref 6 DAC biotechnology company product pipeline
Ref 7 MabGen biotechnology company product pipeline
Ref 8 Pheno therapeutics product pipeline
Ref 9 Prospective grant of an exclusive patent license: anti-CD56 as an antibody-drug conjugate or non-ADC to target glioblastoma either alone or in combination with other potential immuno-oncology drugs; 2020
Ref 10 Introduction to basic information on ADC drug 3-NAntC
Ref 11 ADC review: basic information about ABGN-108.
Ref 12 Defence Therapeutics company product pipeline in Development.
Ref 13 Medilink biotechnology company product pipeline
Ref 14 Arbelebio R&D pipeline.
Ref 15 AIMEDBIO biotechnology company product pipeline.
Ref 16 Introduction to basic information on ADC drug AMB-101
Ref 17 Introduction to basic information on monoclonal antibody-drug conjugate(Antengene).
Ref 18 Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo. Cancer Res (2021) 81 (13_Supplement): 921.
Ref 19 Introduction to basic information on ADC drug antibody-drug conjugate containing OXS-2175(Oxis Biotech/MultiCell ImmunoTherapeutics).
Ref 20 Vaccinex and catalent biologics to collaborate on ADC development; 2017
Ref 21 Aphios biotechnology company product pipeline
Ref 22 Y-Biologics biotechnology company product pipeline
Ref 23 AVIPEP Therapeutics product pipeline
Ref 24 Introduction to basic information on ADC drug BC5084 by Veri.larvol.
Ref 25 boostimmune biotechnology company product pipeline
Ref 26 Biocytogen biotechnology company product pipeline
Ref 27 Introduction to basic information on ADC drug bi-specific antibody drug conjugates(Zymeworks).
Ref 28 ADC review: basic information about BL-B029A1.
Ref 29 ADC review: basic information about BL-M002A2.
Ref 30 Introduction to basic information on ADC drug BL-M005.
Ref 31 ADC review: basic information about BL-M005A2.
Ref 32 Biokin pharma Prospectus; 2022
Ref 33 Introduction to basic information on ADC drug BMT-125961.
Ref 34 JINFA pharmaceutical company product pipeline
Ref 35 Bioray R&D pipeline.
Ref 36 Brickbio biotechnology company product pipeline
Ref 37 Introduction to basic information on BsAb-ADC (Medilink Therapeutics).
Ref 38 Introduction to basic information on ADC drug BSC-4101
Ref 39 Introduction to basic information on ADC drug BSC-4201.
Ref 40 Introduction to basic information on ADC drug CAT-03-106.
Ref 41 Introduction to basic information on ADC drug CBP-1609.
Ref 42 Cybrexa therapeutics product pipeline
Ref 43 Introduction to basic information on ADC drug CM-09(Curemeta).
Ref 44 Cstone pharma product pipeline
Ref 45 Introduction to basic information on ADC drug DN-028.
Ref 46 ADC review: basic information about EP-400.
Ref 47 Introduction to basic information on ADC drug EX108.
Ref 48 FutureGen R&D pipeline.
Ref 49 Introduction to basic information on ADC drug G-100 (Magenta Therapeutics).
Ref 50 Introduction to basic information on ADC drug GF-2014.
Ref 51 Gmax biopharm biopharmaceutical company product pipeline
Ref 52 Genequantum biopharmaceutical company product pipeline
Ref 53 Heidelberg pharma product pipeline
Ref 54 Huiyu pharma semi-annual report; 2022
Ref 55 Iksuda therapeutics product pipeline
Ref 56 Immunobiochem biotechnology company product pipeline
Ref 57 Introduction to basic information on ADC drug JY-023.
Ref 58 Enduring biotechnology company product pipeline
Ref 59 Kangabio biotechnology company product pipeline
Ref 60 ADC review: basic information about LCB14-15NM.
Ref 61 Legochem biosciences biopharmaceutical company product pipeline
Ref 62 Lanova medicines biotechnology company product pipeline
Ref 63 Introduction to basic information on ADC drug LIN-003.
Ref 64 Mablink bioscience company product pipeline
Ref 65 Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 66 Kind Pharmaceuticals LLC company product pipeline.
Ref 67 Micurx biopharmaceutical company product pipeline
Ref 68 Introduction to basic information on ADC drug NBE-001.
Ref 69 Introduction to basic information on ADC drug NBE-003.
Ref 70 NewBio Therapeutics company product pipeline
Ref 71 NewBio Therapeutics company product pipeline
Ref 72 NewBio Therapeutics company product pipeline
Ref 73 Introduction to basic information on next generation antibody-drug conjugates(Oxford BioTherapeutics).
Ref 74 Nectin therapeutics biotechnology company product pipeline
Ref 75 An overview of NW-001.
Ref 76 Oxford Biotherapeutics product pipeline
Ref 77 Introduction to basic information on ADC drug OX-004.
Ref 78 Oligomerization improves endostatin as antiangi-ogenic and anticancer drug (P-1000)
Ref 79 Enduring biotechnology company product pipeline
Ref 80 Epinogen biotechnology company product pipeline
Ref 81 PrimeLink bio therapeutics product pipeline
Ref 82 PrecisemAb biotechnology company product pipeline
Ref 83 Post translational modification therapeutics product pipeline
Ref 84 Introduction to basic information on ADC drug RAD-501.
Ref 85 Next generation drug conjugates for cancer treatment.
Ref 86 Research programme: glycodesigned biotherapeutics (SeeloMab-GEX)-Glycotope; 28 Mar 2018.
Ref 87 Introduction to basic information on ADC drug SGN-25.
Ref 88 Introduction to basic information on ADC drug SI-B-004A.
Ref 89 Introduction to basic information on ADC drug SI-M-002A.
Ref 90 Introduction to basic information on ADC drug SI-M-005A.
Ref 91 Introduction to basic information on ADC drug SMD-3117.
Ref 92 Xiling yuan pharmaceutical company product pipeline
Ref 93 Antibody drug conjugates SOT107
Ref 94 Antibody drug conjugates SOT106
Ref 95 Introduction to basic information on ADC drug Spliceostatin-antibody-drug conjugate
Ref 96 F-star biotechnology company product pipeline
Ref 97 Symray biopharmaceutical company product pipeline
Ref 98 Introduction to basic information on ADC drug SY-1558
Ref 99 Tot biopharm annual announcement; 2021
Ref 100 Heidelberg pharma ATACs fighting cancer; 2020
Ref 101 Topmunnity therapeutics company product pipeline
Ref 102 https://tubulis.com/
Ref 103 ADC review: basic information about VIS705.
Ref 104 Introduction to basic information on ADC drug VLS-201.
Ref 105 Westlake therapeutics product pipeline
Ref 106 Mersana biopharmaceutical company product pipeline
Ref 107 RemeGen biopharmaceutical company clinical-stage drug candidates and selected IND-enabling stage candidates; 30 Jun 2022.
Ref 108 Evopoint biosciences product pipeline
Ref 109 ADC drug XYD-9668-198 antibody conjugating agent for injection passed the review of the State Drug Administration Drug Review Center and was granted implied permission for clinical trials.
Ref 110 Introduction to basic information on ADC drug 131I-ImmuRAIT-HCG (Immunomedics).
Ref 111 NewBio Therapeutics company product pipeline
Ref 112 Introduction to basic information on ADC drug ADC2154
Ref 113 Introduction to basic information on ADC drug ADC2231
Ref 114 Introduction to basic information on ADC drug ADC2313
Ref 115 Introduction to basic information on ADC drug ADC2317
Ref 116 Introduction to basic information on ADC drug ADC2335
Ref 117 Introduction to basic information on ADC drug additional ADCs (Virtuoso Therapeutics).
Ref 118 Adcentrx therapeutics product pipeline
Ref 119 Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 120 Introduction to basic information on ADC drug AK 30 NGF; 27 Nov 2000.
Ref 121 Introduction to basic information on alpha-amanitin antibody-drug conjugates(Agensys).
Ref 122 AmMax biotechnology company product pipeline
Ref 123 TAE Life Sciences company product pipeline
Ref 124 Research programme : antibody drug conjugate-Halozyme; 28 Feb 2021.
Ref 125 Introduction to basic information on ADC drug Antibody drug conjugate containing duocarmycin analogue
Ref 126 Oxford biotherapeutics and boehringer ingelheim agree on 2 year extension to their second multi-year collaboration in cancer immunology; 2023
Ref 127 Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates; 2022
Ref 128 Synaffix is a biotechnology company product pipeline
Ref 129 Introduction to basic information on antibody-drug conjugate 3(Synthon).
Ref 130 Introduction to basic information on antibody-drug conjugate 4(Synthon).
Ref 131 Introduction to basic information on monoclonal anti-cancer therapeutic (Amgen).
Ref 132 Introduction to basic information on ADC drug Antiviral Fc-conjugates(Cidara Therapeutics).
Ref 133 Introduction to basic information on ADC drug APB-CS
Ref 134 Introduction to basic information on ADC drug APEC-2.
Ref 135 Introduction to basic information on ADC drug APEC-3.
Ref 136 Introduction to basic information on ADC drug AT-00
Ref 137 Axcynsis therapeutics product pipeline
Ref 138 Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors. Cancer Immunol Immunother. 2023 Jul;72(7):2405-2422. doi: 10.1007/s00262-023-03425-3. Epub 2023 Mar 30.
Ref 139 Bliss Biopharmaceutical company product pipeline
Ref 140 Boostimmune R&D pipeline.
Ref 141 Introduction to basic information on ADC drug BIOO-1.
Ref 142 Introduction to basic information on ADC drug BIOO-2.
Ref 143 Introduction to basic information on ADC drug BIOO-3.
Ref 144 Introduction to basic information on ADC drug BIOO-4.
Ref 145 An overview of BR107.
Ref 146 Brickbio biotechnology company product pipeline
Ref 147 An overview of BRY811.
Ref 148 Introduction to basic information on ADC drug BSI-023.
Ref 149 Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition.
Ref 150 Introduction to basic information on ADC drug CRB-2107.
Ref 151 Cstonepharma R&D pipeline.
Ref 152 Introduction to basic information on ADC drug CT-P26.
Ref 153 Introduction to basic information on ADC drug DBAF-301.
Ref 154 Introduction to basic information on ADC drug DN-027.
Ref 155 Safety Assessment of Antibody Drug Conjugates.
Ref 156 An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells. Cancer Res (2019) 79 (13_Supplement): 232.
Ref 157 Introduction to basic information on eribulin ADC (Jiangsu hengrui)
Ref 158 EvolveImmune therapeutics product pipeline
Ref 159 Introduction to basic information on ADC drug Gbm12401.
Ref 160 Introduction to basic information on ADC drug GL-231
Ref 161 Introduction to basic information on ADC drug glaucoma therapy(Houston).
Ref 162 Introduction to basic information on ADC drug GMA-305.
Ref 163 Innoventbio 2022 Annual Performance Report.
Ref 164 ADC review IMB-202
Ref 165 Introduction to basic information on ADC drug IN30718.
Ref 166 Inxmed R&D pipeline.
Ref 167 Introduction to basic information on ADC drug IOG-101.
Ref 168 Legochem biosciences: Biopharmaceutical company with robust milestone potential; 2019
Ref 169 Blueshield pharma product pipeline
Ref 170 Introduction to basic information on ADC drug lead ADC (Virtuoso Therapeutics).
Ref 171 Introduction to basic information on ADC drug LP-A18.
Ref 172 Futuregen biopharmaceutical company product pipeline
Ref 173 Manhattan biotech company product pipeline
Ref 174 Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 175 Introduction to basic information on ADC drug MBC-301
Ref 176 Introduction to basic information on ADC drug monoclonal Antibody-Drug Conjugates(Celltrion Chemical Research Institute/Immunogen/Celltrion).
Ref 177 Introduction to basic information on ADC drug MRG006.
Ref 178 NewBio Therapeutics company product pipeline
Ref 179 Introduction to basic information on ADC drug NW-12-005.
Ref 180 Neoletix biotechnology company product pipeline
Ref 181 Denali Therapeutics 2021.
Ref 182 Pinotbio biotechnology company product pipeline
Ref 183 Syntab therapeutics biotechnology company product pipeline
Ref 184 Introduction to basic information on ADC drug second ADC (Virtuoso Therapeutics).
Ref 185 Sirenas biotechnology company announcement; 2016
Ref 186 Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies; 2022
Ref 187 ADC review: basic information about TGM-002.
Ref 188 ADC review: basic information about TGM-003.
Ref 189 ADC review: basic information about TGM-004.
Ref 190 ADC review: basic information about TGM-005.
Ref 191 Transcenta Holding Limited 2022 annual report.
Ref 192 Introduction to basic information on ADC drug Vas-201.
Ref 193 Introduction to basic information on ADC drug Vas-202.
Ref 194 Introduction to basic information on ADC drug VLS-301.
Ref 195 Introduction to basic information on ADC drug ZV03-ADC.
Ref 196 Introduction to basic information on ADC drug Antibody drug conjugate (Asana BioSciences)
Ref 197 Compugen's antibody drug conjugate program results presented; 19 Oct 2015.
Ref 198 Five prime therapeutics licenses antibodies to seattle genetics for use in novel antibody drug conjugate (ADC) programs; 2020
Ref 199 Introduction to basic information on antibody drug conjugates(Intrexon).
Ref 200 Meditope biosciences presentation; 2014
Ref 201 Introduction to basic information on antibody drug conjugates(Sanofi).
Ref 202 Bristol-myers squibb and ambrx announce collaboration for novel biologics programs in diabetes and heart failure
Ref 203 Introduction to basic information on antibody-drug conjugates(Daiichi Sankyo).
Ref 204 Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto; 28 Nov 2020.
Ref 205 Immunobiochem corporation partners with the centre for the commercialization of antibodies and biologics at the university of toronto to advance new antibody drug conjugates; 2016
Ref 206 University of Virginia spinoff neoantigenics announces collaboration with Pfizer, investment from CIT to develop antibody-based therapeutics for cancer; 2014
Ref 207 Introduction to basic information on ADC drug BIOO-5.
Ref 208 Introduction to basic information on ADC drug BIOO-6.
Ref 209 Introduction to basic information on ADC drug BIOO-7.
Ref 210 Introduction to basic information on ADC drug CRC-02 targeting antibody-drug conjugate(Igenica).
Ref 211 Introduction to basic information on ADC drug CYP-Ab.
Ref 212 Introduction to basic information on ADC drug LM-317.
Ref 213 ADC review: basic information about LCB14-2NM.
Ref 214 Introduction to basic information on ADC drug LIN-003.
Ref 215 Introduction to basic information on antibodies conjugated to marine-derived cytotoxic payloads(Seattle Genetics).
Ref 216 Introduction to basic information on ADC drug monovalent azymatic antibody drug conjugate(Zymeworks).
Ref 217 Introduction to basic information on ADC drug MRG005.
Ref 218 Introduction to basic information on ADC drug MRG007.
Ref 219 Introduction to basic information on ADC drug MRG008.
Ref 220 Introduction to basic information on ADC drug MRG009.
Ref 221 Introduction to basic information on ADC drug multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene).